HomeComparePOLXF vs VICI

POLXF vs VICI: Dividend Comparison 2026

POLXF yields 100.70% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 POLXF wins by $3.02M in total portfolio value
10 years
POLXF
POLXF
● Live price
100.70%
Share price
$1.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.01M
Annual income
$1,357,581.74
Full POLXF calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — POLXF vs VICI

📍 POLXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPOLXFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, POLXF + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
POLXF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

POLXF
Annual income on $10K today (after 15% tax)
$8,559.92/yr
After 10yr DRIP, annual income (after tax)
$1,153,944.48/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, POLXF beats the other by $624,172.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of POLXF + VICI for your $10,000?

POLXF: 50%VICI: 50%
100% VICI50/50100% POLXF
Portfolio after 10yr
$2.50M
Annual income
$990,421.53/yr
Blended yield
39.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

POLXF
No analyst data
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

POLXF buys
0
VICI buys
0
No recent congressional trades found for POLXF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPOLXFVICI
Forward yield100.70%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$4.01M$988.8K
Annual income after 10y$1,357,581.74$623,261.32
Total dividends collected$3.58M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: POLXF vs VICI ($10,000, DRIP)

YearPOLXF PortfolioPOLXF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$20,770$10,070.49$11,368$948.43+$9.4KPOLXF
2$41,773$19,548.52$13,339$1,493.16+$28.4KPOLXF
3$81,440$36,743.31$16,326$2,426.21+$65.1KPOLXF
4$154,089$66,948.23$21,123$4,112.15+$133.0KPOLXF
5$283,258$118,382.76$29,379$7,368.23+$253.9KPOLXF
6$506,470$203,383.03$44,804$14,191.64+$461.7KPOLXF
7$881,783$339,861.07$76,658$29,972.12+$805.1KPOLXF
8$1,496,510$553,001.45$150,894$71,015.81+$1.35MPOLXF
9$2,478,388$877,122.18$350,814$193,582.47+$2.13MPOLXF
10$4,009,457$1,357,581.74$988,809$623,261.32+$3.02MPOLXF

POLXF vs VICI: Complete Analysis 2026

POLXFStock

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. Further, it supplies ferric hydroxide and hydrogenated dextran solutions. The company sells its products through independent distributors and wholesalers, as well as directly to companies. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada.

Full POLXF Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this POLXF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

POLXF vs SCHDPOLXF vs JEPIPOLXF vs OPOLXF vs KOPOLXF vs MAINPOLXF vs NNNPOLXF vs EPRTPOLXF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.